ERNEST HAWK to Eflornithine
This is a "connection" page, showing publications ERNEST HAWK has written about Eflornithine.
Connection Strength
0.832
-
An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis. Gut. 2016 Feb; 65(2):286-95.
Score: 0.518
-
Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila). 2008 Jun; 1(1):32-8.
Score: 0.081
-
Irreversible ototoxicity associated with difluoromethylornithine. Cancer Epidemiol Biomarkers Prev. 2004 Jul; 13(7):1250-2.
Score: 0.062
-
The future of colon cancer prevention. Ann N Y Acad Sci. 2001 Dec; 952:88-108.
Score: 0.052
-
Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res. 2000 Apr 01; 60(7):1864-70.
Score: 0.046
-
Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. Carcinogenesis. 1999 Mar; 20(3):425-30.
Score: 0.043
-
Strategy for prevention of cancers of the esophagus. Ann N Y Acad Sci. 2014 Sep; 1325:108-26.
Score: 0.031